Lung cancer is a public health priority worldwide due to the high mortality rate and the costs involved .
However , when used alone they show low sensitivity and specificity because lung cancer is a heterogeneous disease .
Recent reports have shown that simultaneous analysis of biomarkers has the potential to separate lung cancer patients from control subjects .
However , it has become clear that a universal biomarker panel does not exist , and optimized panels need to be developed and validated in each population before their application in a clinical setting .

